CardioLogic Innovations
Lung Fluid Level Monitoring
Company Overview
Snapshot
Founded in June 2012 by Shay Faitelzon, CardioLogic Innovations operated with 1–10 employees. The company developed a patented platform technology for monitoring lung fluid levels, a significant advancement in preventing acute heart failure hospitalizations. The company ceased operations in April 2018.
Business overview
CardioLogic Innovations developed a patented platform technology focused on precision monitoring of fluid levels in each lung. This technology aimed to prevent acute heart failure hospitalizations by providing noninvasive devices for inpatient, outpatient, and home use. The company also offered an integrative solution designed to enhance existing implantable cardiac resynchronization therapy and implantable cardioverter defibrillator devices, operating within the Health Tech & Life Sciences sector, specifically in medical devices and digital healthcare for patient remote monitoring.
Log in to access full profile ›Company Intelligence Q&A
- What is CardioLogic Innovations' primary focus?
- CardioLogic Innovations developed a patented platform technology for precise monitoring of fluid levels in each lung, aiming to prevent acute heart failure hospitalizations.
- When was CardioLogic Innovations founded?
- CardioLogic Innovations was founded in June 2012.
- Who is a founder of CardioLogic Innovations?
- Shay Faitelzon is a co-founder of CardioLogic Innovations.
- What was the operational status of CardioLogic Innovations?
- CardioLogic Innovations ceased to operate in April 2018.
- What type of products did CardioLogic Innovations develop?
- CardioLogic Innovations developed noninvasive devices for inpatient, outpatient, and home use, as well as an integrative solution for enhancing implantable cardiac devices.